• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology.

作者信息

Yoon Eileen Laurel, Jun Dae Won

机构信息

Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):371-373. doi: 10.3350/cmh.2023.0086. Epub 2023 Mar 14.

DOI:10.3350/cmh.2023.0086
PMID:36916169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121300/
Abstract
摘要

相似文献

1
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology.将术语从非酒精性脂肪性肝病改为代谢功能障碍相关脂肪性肝病，这不仅仅是术语的改变。
Clin Mol Hepatol. 2023 Apr;29(2):371-373. doi: 10.3350/cmh.2023.0086. Epub 2023 Mar 14.
2
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.非酒精性脂肪性肝病与代谢相关脂肪性肝病：名称改变的流行率、结局及意义。
Clin Mol Hepatol. 2022 Oct;28(4):790-801. doi: 10.3350/cmh.2022.0070. Epub 2022 May 11.
3
The Future of Nonalcoholic Fatty Liver Disease Treatment.非酒精性脂肪性肝病治疗的未来。
Med Clin North Am. 2019 Jan;103(1):57-69. doi: 10.1016/j.mcna.2018.08.005. Epub 2018 Nov 1.
4
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.MAFLD：代谢相关脂肪性肝病的共识驱动命名建议。
Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.
5
Cardiovascular Risk in Children with Nonalcoholic Fatty Liver Disease (NAFLD).非酒精性脂肪性肝病（NAFLD）患儿的心血管风险
Curr Pediatr Rev. 2020;16(4):294-297. doi: 10.2174/1573396316666201009154913.
6
Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).同时性代谢性和酒精相关性脂肪性肝病（SMAFLD）以及同时性代谢性和酒精相关性脂肪性肝炎（SMASH）。
Ann Hepatol. 2021 Sep-Oct;24:100526. doi: 10.1016/j.aohep.2021.100526.
7
Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.非酒精性脂肪性肝病是代谢健康人群代谢性疾病的早期预测指标。
PLoS One. 2019 Nov 4;14(11):e0224626. doi: 10.1371/journal.pone.0224626. eCollection 2019.
8
A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.一个缩写中的一个字母变化：从非酒精性脂肪性肝病 (NAFLD) 到代谢相关性脂肪性肝病 (MAFLD) 的信号、原因、承诺、挑战和前进步骤。
Expert Rev Gastroenterol Hepatol. 2021 Apr;15(4):345-352. doi: 10.1080/17474124.2021.1860019. Epub 2020 Dec 9.
9
Letter to the Editor: Nonalcoholic Fatty Liver Disease Without Metabolic-Associated Fatty Liver Disease and Metabolic Syndrome.致编辑的信：无代谢相关脂肪性肝病及代谢综合征的非酒精性脂肪性肝病
Clin Gastroenterol Hepatol. 2023 Aug;21(9):2435. doi: 10.1016/j.cgh.2022.10.034. Epub 2022 Nov 11.
10
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults.老年人群中非酒精性脂肪性肝病与晚年发生痴呆症的关联。
Clin Mol Hepatol. 2022 Jul;28(3):481-482. doi: 10.3350/cmh.2022.0097. Epub 2022 May 16.

引用本文的文献

1
Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis.基于转录组分析的代谢功能障碍相关脂肪性肝病的分子聚类
Diagnostics (Basel). 2025 Jan 31;15(3):342. doi: 10.3390/diagnostics15030342.
2
Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis.通过机器学习和免疫分析鉴定早期生长反应蛋白1（EGR1）作为代谢功能障碍相关脂肪性肝病（MASLD）的关键诊断生物标志物
J Inflamm Res. 2025 Feb 4;18:1639-1656. doi: 10.2147/JIR.S499396. eCollection 2025.
3
Exploring the relationship between air pollution, non-alcoholic fatty liver disease, and liver function indicators: a two-sample Mendelian randomization analysis study.探索空气污染、非酒精性脂肪性肝病和肝功能指标之间的关系：一项两样本孟德尔随机化分析研究。
Front Endocrinol (Lausanne). 2024 Nov 29;15:1396032. doi: 10.3389/fendo.2024.1396032. eCollection 2024.
4
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences.五种心脏代谢危险因素在代谢功能障碍相关脂肪性肝病（MASLD）中的临床影响：对地区和种族差异的见解
Clin Mol Hepatol. 2024 Apr;30(2):168-170. doi: 10.3350/cmh.2024.0140. Epub 2024 Mar 5.
5
Correspondence on Letter regarding "Waiting for the changes after the adoption of steatotic liver disease".关于“等待脂肪性肝病采用后的变化”信件的通信
Clin Mol Hepatol. 2024 Jan;30(1):126-128. doi: 10.3350/cmh.2023.0500. Epub 2023 Nov 28.
6
The heated debate over NAFLD renaming: An ongoing saga.关于非酒精性脂肪性肝病（NAFLD）更名的激烈争论：一个仍在继续的故事。
Hepatol Forum. 2023 Sep 7;4(3):89-91. doi: 10.14744/hf.2023.2023.0044. eCollection 2023.
7
Waiting for the changes after the adoption of steatotic liver disease.等待肝脂肪变性疾病采用后的变化。
Clin Mol Hepatol. 2023 Oct;29(4):844-850. doi: 10.3350/cmh.2023.0291. Epub 2023 Sep 6.

本文引用的文献

1
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives.慢性乙型肝炎合并代谢相关脂肪性肝病：挑战与展望。
Clin Mol Hepatol. 2023 Apr;29(2):320-331. doi: 10.3350/cmh.2022.0422. Epub 2023 Feb 1.
2
Examining the interim proposal for name change to steatotic liver disease in the US population.探讨美国人群中肝脂肪变性疾病名称变更的临时建议。
Hepatology. 2023 May 1;77(5):1712-1721. doi: 10.1097/HEP.0000000000000043. Epub 2023 Jan 3.
3
Risk factors in nonalcoholic fatty liver disease.非酒精性脂肪性肝病的危险因素。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S79-S85. doi: 10.3350/cmh.2022.0398. Epub 2022 Dec 14.
4
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response.非酒精性脂肪性肝病的遗传学：免疫应答视角下的风险等位基因作用。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S184-S195. doi: 10.3350/cmh.2022.0318. Epub 2022 Dec 5.
5
Interaction between sarcopenia and nonalcoholic fatty liver disease.肌少症与非酒精性脂肪性肝病的相互作用。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S68-S78. doi: 10.3350/cmh.2022.0358. Epub 2022 Dec 5.
6
MAFLD: How is it different from NAFLD?MAFLD：与非酒精性脂肪性肝病（NAFLD）有何不同？
Clin Mol Hepatol. 2023 Feb;29(Suppl):S17-S31. doi: 10.3350/cmh.2022.0367. Epub 2022 Nov 29.
7
Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature.等待多方利益相关者关于非酒精性脂肪性肝病新命名法的共识立场声明。
Gut Liver. 2022 May 15;16(3):319-320. doi: 10.5009/gnl220183.
8
Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.韩国代谢相关脂肪性肝病患者中晚期肝纤维化和合并症的患病率。
Liver Int. 2022 Jul;42(7):1536-1544. doi: 10.1111/liv.15259. Epub 2022 Apr 12.
9
Global multi-stakeholder endorsement of the MAFLD definition.全球多方利益相关者对MAFLD定义的认可。
Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3.
10
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.MAFLD改善了亚太地区肝脏疾病的临床实践。
Clin Mol Hepatol. 2022 Apr;28(2):150-163. doi: 10.3350/cmh.2021.0310. Epub 2021 Nov 10.